Last reviewed · How we verify
DOR
DOR is a delta opioid receptor agonist that binds to and activates delta opioid receptors in the central and peripheral nervous system.
DOR is a delta opioid receptor agonist that binds to and activates delta opioid receptors in the central and peripheral nervous system. Used for Chronic pain conditions.
At a glance
| Generic name | DOR |
|---|---|
| Also known as | Doravirine, MK-1439 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Delta opioid receptor agonist |
| Target | Delta opioid receptor (DOR) |
| Modality | Small molecule |
| Therapeutic area | Pain management / Neurology |
| Phase | FDA-approved |
Mechanism of action
Delta opioid receptors are G-protein coupled receptors involved in pain modulation, mood regulation, and other physiological processes. By selectively activating these receptors, DOR produces analgesic and potentially mood-enhancing effects. The selective delta agonism may offer a different safety and efficacy profile compared to mu opioid receptor agonists.
Approved indications
- Chronic pain conditions
Common side effects
- Dizziness
- Nausea
- Headache
- Somnolence
Key clinical trials
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (PHASE3)
- Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy
- Effect of Thumbtack Needle (TN) on Ovarian Reserve Function of Women With Diminished Ovarian Reserve (DOR) (NA)
- Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) (PHASE2)
- A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061) (PHASE1)
- Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017) (PHASE3)
- LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm
- Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |